A Practical, Evidence-informed Approach to Managing Stimulant-Refractory Attention Deficit Hyperactivity Disorder (ADHD) Samuele CorteseJeffrey H. NewcornDavid Coghill Therapy in Practice 17 August 2021 Pages: 1035 - 1051
Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta-Analysis Gerald GartlehnerKaren CrottyMeera Viswanathan Systematic Review Open access 08 September 2021 Pages: 1053 - 1067
Evaluating the Role of Ketamine/Esketamine in the Management of Major Depressive Disorder with Suicide Risk Sina NikayinGerard Sanacora Review Article 07 September 2021 Pages: 1069 - 1079
Pharmacotherapy for Neuropsychiatric Symptoms in Frontotemporal Dementia Christine LeElizabeth Finger Review Article 24 August 2021 Pages: 1081 - 1096
Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009–2018 Nahid MoradiSifat SharminMSBase Study Group Original Research Article 23 June 2021 Pages: 1097 - 1106
Efficacy, Retention and Tolerability of Everolimus in Patients with Tuberous Sclerosis Complex: A Survey-Based Study on Patients’ Perspectives Laurent M. WillemsFelix RosenowAdam Strzelczyk Original Research Article Open access 17 July 2021 Pages: 1107 - 1122
Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia John LaurielloPeter J. WeidenAmy K. O’Sullivan Original Research Article Open access 21 September 2021 Pages: 1123 - 1135
Comment on “Erythropoietin Improves Poor Outcomes in Preterm Infants with Intraventricular Hemorrhage” Anita ChevleAnish PillaiNandkishor Kabra Letter to the Editor 04 September 2021 Pages: 1137 - 1138
Authors’ Reply to Chevle et al.: Comment on “Erythropoietin Improves Poor Outcomes in Preterm Infants with Intraventricular Hemorrhage” Juan SongYong WangChanglian Zhu Letter to the Editor 04 September 2021 Pages: 1139 - 1140
